Literature DB >> 19651670

Association of serum myeloperoxidase with the ankle-brachial index and peripheral arterial disease.

Zeenat Ali1, Paul Sarcia, Thomas H Mosley, Venkateswarlu Kondragunta, Iftikhar J Kullo.   

Abstract

Myeloperoxidase (MPO) is an enzymatic mediator of several inflammatory cascades and higher serum levels have been associated with increased risk of adverse cardiovascular events. We investigated the association of serum MPO with the ankle-brachial index (ABI) and peripheral arterial disease (PAD) in a bi-ethnic cohort of African-Americans and non-Hispanic white individuals. Participants included 1324 African-Americans (mean age 64 years, 71% women) and 1237 non-Hispanic white individuals (mean age 59 years, 57% women) belonging to hypertensive sibships. Serum levels of MPO were measured by solid phase sandwich immunoassay. ABI was measured using a standard protocol and PAD was defined as an ABI < 0.90. Multivariable regression analysis using generalized estimating equations were performed to assess whether serum MPO levels were associated with ABI and the presence of PAD. After adjustment for age and sex, higher MPO levels were significantly associated with lower ABI and the presence of PAD in African-Americans (p = 0.004 and p = 0.005, respectively) and in non-Hispanic white individuals (p = 0.001 and p = 0.016, respectively). After additional adjustment for conventional risk factors (diabetes, smoking status, total and high-density lipoprotein cholesterol, waist circumference, hypertension), prior history of myocardial infarction or stroke, and medication use (statins, aspirin, estrogen), higher MPO levels remained significantly associated with lower ABI and the presence of PAD in both African-Americans (p = 0.008 and p = 0.010, respectively) and non-Hispanic white individuals (p = 0.001 and p = 0.018, respectively). We conclude that higher MPO levels are associated with lower ABI and the presence of PAD in African-Americans and non-Hispanic white individuals.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19651670      PMCID: PMC2752685          DOI: 10.1177/1358863X08101999

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  42 in total

1.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

2.  Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils.

Authors:  G J Peppin; S J Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

3.  Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima.

Authors:  C Leeuwenburgh; M M Hardy; S L Hazen; P Wagner; S Oh-ishi; U P Steinbrecher; J W Heinecke
Journal:  J Biol Chem       Date:  1997-01-17       Impact factor: 5.157

4.  The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport.

Authors:  Constanze Bergt; Subramaniam Pennathur; Xiaoyun Fu; Jaeman Byun; Kevin O'Brien; Thomas O McDonald; Pragya Singh; G M Anantharamaiah; Alan Chait; John Brunzell; Randolph L Geary; John F Oram; Jay W Heinecke
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

5.  Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.

Authors:  Lemin Zheng; Benedicta Nukuna; Marie-Luise Brennan; Mingjiang Sun; Marlene Goormastic; Megan Settle; Dave Schmitt; Xiaoming Fu; Leonor Thomson; Paul L Fox; Harry Ischiropoulos; Jonathan D Smith; Michael Kinter; Stanley L Hazen
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

6.  Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions.

Authors:  A Daugherty; J L Dunn; D L Rateri; J W Heinecke
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

Review 7.  Oxygen metabolism and the toxic properties of phagocytes.

Authors:  S J Klebanoff
Journal:  Ann Intern Med       Date:  1980-09       Impact factor: 25.391

8.  Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins.

Authors:  J W Heinecke; W Li; G A Francis; J A Goldstein
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

9.  Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages.

Authors:  L J Hazell; R Stocker
Journal:  Biochem J       Date:  1993-02-15       Impact factor: 3.857

10.  Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study.

Authors:  John G O'Meara; Sharon L R Kardia; Jeffrey J Armon; C Andrew Brown; Eric Boerwinkle; Stephen T Turner
Journal:  Arch Intern Med       Date:  2004-06-28
View more
  12 in total

Review 1.  Myeloperoxidase production by macrophage and risk of atherosclerosis.

Authors:  Mahir Karakas; Wolfgang Koenig
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

2.  Peripheral arterial disease, prevalence and cumulative risk factor profile analysis.

Authors:  Luis H Eraso; Eri Fukaya; Emile R Mohler; Dawei Xie; Daohang Sha; Jeffrey S Berger
Journal:  Eur J Prev Cardiol       Date:  2012-06-27       Impact factor: 7.804

Review 3.  Biomarkers and Genetics in Peripheral Artery Disease.

Authors:  Surovi Hazarika; Brian H Annex
Journal:  Clin Chem       Date:  2016-11-21       Impact factor: 8.327

4.  Race-specific associations of myeloperoxidase with atherosclerosis in a population-based sample: the Dallas Heart Study.

Authors:  Lu Q Chen; Anand Rohatgi; Colby R Ayers; Sandeep R Das; Amit Khera; Jarett D Berry; Darren K McGuire; James A de Lemos
Journal:  Atherosclerosis       Date:  2011-08-22       Impact factor: 5.162

5.  Traditional and non-traditional risk factors for incident peripheral arterial disease among patients with chronic kidney disease.

Authors:  Jing Chen; Emile R Mohler; Dawei Xie; Michael Shlipak; Raymond R Townsend; Lawrence J Appel; Akinlolu Ojo; Martin Schreiber; Lisa Nessel; Xiaoming Zhang; Dominic Raj; Louise Strauss; Claudia M Lora; Mahboob Rahman; L Lee Hamm; Jiang He
Journal:  Nephrol Dial Transplant       Date:  2015-12-18       Impact factor: 5.992

6.  Alcohol consumption and ankle-to-brachial index: results from the Cardiovascular Risk Survey.

Authors:  Xiang Xie; Yi-Tong Ma; Yi-Ning Yang; Xiao-Mei Li; Fen Liu; Ding Huang; Zhen-Yan Fu; Xiang Ma; Bang-Dang Chen; Ying Huang
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

7.  Associations of candidate biomarkers of vascular disease with the ankle-brachial index and peripheral arterial disease.

Authors:  Zi Ye; Zeenat Ali; George G Klee; Thomas H Mosley; Iftikhar J Kullo
Journal:  Am J Hypertens       Date:  2013-01-11       Impact factor: 2.689

Review 8.  Novel markers of peripheral arterial disease.

Authors:  Farhan J Khawaja; Iftikhar J Kullo
Journal:  Vasc Med       Date:  2009-11       Impact factor: 3.239

9.  N-acetyl lysyltyrosylcysteine amide inhibits myeloperoxidase, a novel tripeptide inhibitor.

Authors:  Hao Zhang; Xigang Jing; Yang Shi; Hao Xu; Jianhai Du; Tongju Guan; Dorothee Weihrauch; Deron W Jones; Weiling Wang; David Gourlay; Keith T Oldham; Cheryl A Hillery; Kirkwood A Pritchard
Journal:  J Lipid Res       Date:  2013-07-24       Impact factor: 5.922

Review 10.  The role of novel atherosclerosis markers in peripheral artery disease: is there a gender difference?

Authors:  Hora Iu Comşa; Dumitru Zdrenghea; Sorin Claudiu Man; Dana Pop
Journal:  Cardiovasc J Afr       Date:  2018-04-20       Impact factor: 1.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.